SEC Form 4 · accession 0001209191-17-046035
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander Cumbo
Officer — SVP, Chief Commercial Officer
Period of report
Jul 20, 2017
Accepted (ET)
Jul 21, 2017 · 9:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 20, 2017 | M | 2,500 | $13.71 | A | 22,793 | D | |
| Common StockF1 | Jul 20, 2017 | S | 2,500 | $41.00 | D | 20,293 | D | |
| Common StockF1 | Jul 20, 2017 | S | 3,418 | $41.00 | D | 16,875 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F1 | $13.71 | Jul 20, 2017 | M | 2,500 | D | Feb 28, 2017 | Feb 28, 2026 | Common Stock | 2,500 | 15,774 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction.